Abstract
Pharmacogenomics and its predecessor pharmacogenetics study the contribution of genetic factors to the interindividual variability in drug efficacy and safety. One of the major goals of pharmacogenomics is to tailor drugs to individuals based on their genetic makeup and molecular profile. From early findings in the 1950s uncovering inherited deficiencies in drug metabolism that explained drug-related adverse events, to nowadays genome-wide approaches assessing genetic variation in multiple genes, pharmacogenomics has come a long way. The evolution of pharmacogenomics has paralleled the evolution of genotyping technologies, the completion of the human genome sequencing and the HapMap project. Despite these advances, the implementation of pharmacogenomics in clinical practice has yet been limited. Here we present an overview of the history and current applications of pharmacogenomics in patient selection, dosing, and drug development with illustrative examples of these categories. Some of the challenges in the field and future perspectives are also presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Offit K (2011) Personalized medicine: new genomics, old lessons. Hum Genet 130(1): 3–14
Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3(9):739–748
Kalow W et al (1998) Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8(4):283–289
Evans WE, McLeod HL (2003) Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 348(6):538–549
Roden DM et al (2006) Pharmacogenomics: challenges and opportunities. Ann Intern Med 145(10):749–757
Camilleri M, Saito YA (2008) Pharmacogenomics in gastrointestinal disorders. Methods Mol Biol 448:395–412
Kirk RJ et al (2008) Implications of pharmacogenomics for drug development. Exp Biol Med (Maywood) 233(12):1484–1497
McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101–121
Watters JW, McLeod HL (2003) Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603(2):99–111
Hudson KL (2011) Genomics, health care, and society. N Engl J Med 365(11): 1033–1041
Snyder LH (1932) Studies in human inheritance. IX. The inheritance of taste deficiency in man. Ohio J Sci 32:436–468
Kim UK et al (2003) Positional cloning of the human quantitative trait locus underlying taste sensitivity to phenylthiocarbamide. Science 299(5610):1221–1225
Motulsky AG (1957) Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 165(7):835–837
Vogel F (1959) Moderne probleme der humangenetik. Ergebn Inn Med Kinderheilkd 12:52–125
Nebert DW et al (2008) From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 40(2):187–224
Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63(2):437–459
Gonzalez FJ et al (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331(6155):442–446
Blum M et al (1990) Human arylamine N-acetyltransferase genes - isolation, chromosomal localization, and functional expression. DNA Cell Biol 9(3):193–203
Krynetski EY et al (1995) A single-point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92(4):949–953
Vesell ES (1989) Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 41(3):535–552
Shin J et al (2009) Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm 66(7):625–637
Roden DM et al (2011) Pharmacogenomics: the genetics of variable drug responses. Circulation 123(15):1661–1670
Evans WE, Relling MV (1999) Relling, Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286(5439):487–491
Belle DJ, Singh H (2008) Genetic factors in drug metabolism. Am Fam Physician 77(11): 1553–1560
Gaedigk A et al (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234–242
Desta Z et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913–958
Mini E, Nobili S (2009) Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 6(1):17–24
Venter JC et al (2001) The sequence of the human genome. Science 291(5507): 1304–1351
Lander ES et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921
den Dunnen JT, Antonarakis SE (2001) Nomenclature for the description of human sequence variations. Hum Genet 109(1): 121–124
Kacevska M et al (2011) Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 89(6): 902–907
O’Donnell PH, Dolan ME (2009) Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15(15):4806–4814
Lee W et al (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10(2):104–111
Judson R et al (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics 1(1):15–26
Fujiwara Y, Minami H (2010) An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 11(3):391–406
Becquemont L (2009) Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10(6): 961–969
Wu X et al (2009) Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches. In: Innocenti F (ed) Genomics and pharmacogenomics in anticancer drug development and clinical response. Humana Press, Totowa NJ, pp 353–370
Feero WG et al (2010) Genomic medicine—an updated primer. N Engl J Med 362(21):2001–2011
Metzker ML (2010) Sequencing technologies—the next generation. Nat Rev Genet 11(1):31–46
Wilke RA et al (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6(11):904–916
Andrade RJ et al (2009) Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 10(9):1467–1487
Huang YS (2010) Tailored drug therapy for mitigating drug-induced liver injury: is this the era of genetic screening? Pers Med 7(1):5–8
Wang L et al (2011) Genomics and drug response. N Engl J Med 364(12):1144–1153
Daly AK et al (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41(7):816–819
Kindmark A et al (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8(3):186–195
Singer JB et al (2010) A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42(8):711–714
Tujios S, Fontana RJ (2011) Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 8(4): 202–211
Pirmohamed M (2010) Pharmacogenetics of idiosyncratic adverse drug reactions. Handb Exp Pharmacol 196:477–491
Becquemont L (2010) HLA: a pharmacogenomics success story. Pharmacogenomics 11(3):277–281
Mallal S et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358(6):568–579
Hung SI et al (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16(4):297–306
TEGRETOL(Carbamazepine) Labeling [Online].http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016608s100s102s.s.,018927s041s042,020234s031s033lbl.pdf. Accessed 31 Oct 2011
McCormack M et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364(12):1134–1143
Ozeki T et al (2011) Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20(5):1034–1041
Somkrua R et al (2011) Association of HLA-B*5801 allele and Allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 12(1):118
Niemi M (2010) Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87(1):130–133
Link E et al (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359(8):789–799
Walko CM, McLeod H (2009) Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol 6(3):153–162
Innocenti F, Ratain MJ (2006) Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8):1211–1221
Wilke RA, Dolan ME (2011) Genetics and variable drug response. JAMA 306(3):306–307
Carlquist JF, Anderson JL (2011) Pharmacogenetic mechanisms underlying unanticipated drug responses. Discov Med 11(60):469–478
Lovly CM, Carbone DP (2011) Lung cancer in 2010: one size does not fit all. Nat Rev Clin Oncol 8(2):68–70
Biankin AV, Hudson TJ (2011) Somatic variation and cancer: therapies lost in the mix. Hum Genet 130(1):79–91
Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507–2516
Shaw AT et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004–1012
Hutchinson L (2010) Targeted therapies: activated PI3K/AKT confers resistance to trastuzumab but not lapatinib. Nat Rev Clin Oncol 7(8):424
Ellis LM, Hicklin DJ (2009) Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 15(24):7471–7478
PLAVIX (Clopidogrel) Labeling [Online]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020839s051lbl.pdf. Accessed 28 Aug
Mega JL et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354–362
Mega JL et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16):1821–1830
Scott SA et al (2011) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and Clopidogrel therapy. Clin Pharmacol Ther 90(2):328–332
Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13(5):247–252
Kim MJ et al (2009) A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 49(2):138–146
Scordo MG et al (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702–710
Sconce EA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329–2333
Marsh S et al (2006) Population variation in VKORC1 haplotype structure. J Thromb Haemost 4(2):473–474
Yuan HY et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14(13):1745–1751
Gage BF, Lesko LJ (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25(1):45–51
Caraco Y et al (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83(3):460–470
Gage BF et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84(3): 326–331
Lenzini P et al (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87(5):572–578
COUMADIN (Warfarin) prescribing information. [Online]. www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf. Accessed 28 Aug
Tetrabenazine Clinical Pharmacology Review. [Online]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000TOC.cfm. Accessed 28 Aug
XENAZINE (Tetrabenazine) Labeling [Online]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021894s004lbl.pdf. Accessed 28 Aug
Stingl Kirchheiner JC, Brockmoller J (2011) Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs. Clin Pharmacol Ther 89(2):198–209
Zineh I, Pacanowski MA (2011) Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United states food and drug administration. Pharmacotherapy 31(8):729–735
Diamandis M et al (2010) Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 8(9):1175–1187
Houle D et al (2010) Phenomics: the next challenge. Nat Rev Genet 11(12):855–866
Pirmohamed M et al (2011) The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 89(6): 784–785
Lanktree MB et al (2010) Phenomics: expanding the role of clinical evaluation in genomic studies. J Investig Med 58(5): 700–706
Tracy RP (2008) ‘Deep phenotyping’: characterizing populations in the era of genomics and systems biology. Curr Opin Lipidol 19(2):151–157
Carson PE et al (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124(3220):484–485
Kalow W (1956) Familial incidence of low pseudocholinesterase level. Lancet 271:576–577
Harris HW et al (1958) Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. Am Rev Tuberc 78(6):944–948
Evans DA et al (1960) Genetic control of isoniazid metabolism in man. Br Med J 2(5197):485–491
Mahgoub A et al (1977) Polymorphic hydroxylation of Debrisoquine in man. Lancet 2(8038):584–586
Eichelbaum M et al (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16(3):183–187
Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651–662
Ge D et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399–401
Eichler HG et al (2011) Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495–506
Bertilsson L et al (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111–122
Janne PA et al (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8(9): 709–723
Acknowledgment
The authors acknowledge Dr. Issam Zineh for critical review of the manuscript.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Charlab, R., Zhang, L. (2013). Pharmacogenomics: Historical Perspective and Current Status. In: Innocenti, F., van Schaik, R. (eds) Pharmacogenomics. Methods in Molecular Biology, vol 1015. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-435-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-435-7_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-434-0
Online ISBN: 978-1-62703-435-7
eBook Packages: Springer Protocols